| |
| Issue |
Title |
| |
| No 12 (2025) |
Anti-CD20 therapy and pregnancy planning in multiple sclerosis |
Abstract
PDF (Rus)
|
|
N. V. Khachanova, V. S. Krasnov, E. P. Evdoshenko, I. V. Zakroyshchikova, D. S. Kasatkin, D. S. Korobko, S. A. Kotiy, P. A. Kuznetsov, E. S. Novikova, E. V. Popova, N. A. Totolyan, N. S. Trifonova, M. V. Shumilina, T. I. Yakushina, M. V. Davydovskaia |
| |
| No 12 (2025) |
Cladribine in tablets in real clinical practice: Results of treatment of 267 patients with multiple sclerosis in Moscow |
Abstract
PDF (Rus)
|
|
E. V. Popova, V. B. Sosina, S. N. Sharanova, S. N. Zolotova, I. M. Shalabanova, N. V. Khachanova, M. V. Davydovskaia, L. Yu. Gorshkova, D. M. Fekhretdinova, N. F. Smirnova, E. V. Ponevezhskaya, A. D. Kukushkina, E. V. Lysogorskaia, E. A. Dubchenko, E. V. Veshchunova, S. E. Belov, N. Sh. Arzumanyan, D. M. Yakushin, A. I. Tatarenko |
| |
| No 12 (2025) |
Administration of siponimod in real clinical practice in Russia |
Abstract
PDF (Rus)
|
|
M. V. Davydovskaia, N. Sh. Arzumanyan, E. A. Dubchenko, V. B. Sosina, M. V. Shumilina, E. V. Krivomlina, L. Yu. Gorshkova, M. V. Sutormin, A. A. Sokolova, K. Z. Bakhtiyarova, A. V. Lelyukhina, M. S. Cherepyansky, E. Р. Evdoshenko |
| |
| No 12 (2024) |
Parenteral anti-B cell therapy for multiple sclerosis: From origins to the creation of the Russian drug divosilimab |
Abstract
PDF (Rus)
|
|
E. V. Popova, S. R. Zeynalova |
| |
| No 12 (2024) |
Early use of cladribine tablets for relapsing-remitting multiple sclerosis: Expert opinion |
Abstract
PDF (Rus)
|
|
E. V. Popova, M. V. Abroskina, K. Z. Bakhtiyarova, Ya. V. Vlasov, M. V. Davydovskaia, E. P. Evdoshenko, D. S. Korobko, A. I. Nilov, M. V. Sutormin, Yu. V. Trinitatskiy, F. A. Khabirov, G. E. Sheiko, M. V. Shumilina |
| |
| No 19 (2021) |
Clinical case of COVID-19 in a patient treated with alemtuzumab |
Abstract
PDF (Rus)
|
|
E. V. Popova |
| |
| No 10 (2021) |
Clinical observation of the course of COVID-19 in patients with multiple sclerosis during ocrelizumab therapy: two clinical cases |
Abstract
PDF (Rus)
|
|
E. V. Popova, M. I. Alexandrov, I. A. Trubnikova, S. R. Zeynalova |
| |
| No 19 (2020) |
Relevance of first-line drugs for treatment of multiple sclerosis in present-day conditions |
Abstract
PDF (Rus)
|
|
N. Yu. Lashch |
| |
| No 8 (2020) |
Monoclonal antibodies in the treatment of multiple sclerosis: from clinical research to practical application |
Abstract
PDF (Rus)
|
|
N. Yu. Lashch |
| |
| No 2 (2020) |
Use of monoclonal antibodies in patients with multiple sclerosis in the practice of a neurologist |
Abstract
PDF (Rus)
|
|
N. Yu. Lashch |
| |
| No 2 (2020) |
The experience of using ocrelizumab in routine practice |
Abstract
PDF (Rus)
|
|
E. V. Popova, S. A. Ryabov |
| |
| No 9 (2019) |
Clinical efficacy and safety of alemtuzumab in postmarketing practice |
Abstract
PDF (Rus)
|
|
N. V. Khachanova |
| |
| No 9 (2019) |
Ocrelizumab therapy and long-term outcomes in multiple sclerosis: clinical and MRI-efficacyand safety profile |
Abstract
PDF (Rus)
|
|
D. L. Klabukova, M. V. Davydovskaya |
| |
| No 9 (2018) |
The algorithm of treatment of the patient with relapsing-remitting multiple sclerosis with suboptimal response:the example of a clinical case |
Abstract
PDF (Rus)
|
|
E. V. Popova, V. V. Bryukhov, A. N. Boyko, M. V. Krotenkova |
| |
| No 1 (2018) |
OCRELIZUMAB IN THE TREATMENT OF PRIMARY-PROGRESSIVE MULTIPLE SCLEROSIS |
Abstract
PDF (Rus)
|
|
E. V. Popova |
| |
| No 1S (2017) |
IMMUNOLOGICAL PRECONDITIONS OF CONVERSION FROM NATALIZUMAB TO FINGOLIMOD |
Abstract
PDF (Rus)
|
|
E. V. Popova, M. V. Melnikov, A. N. Boyko, M. B. Paschenkov |
| |
| No 10 (2017) |
MONOCLONAL ANTIBODY FOR MULTIPLE SCLEROSIS TREATMENT |
Abstract
PDF (Rus)
|
|
E. V. Popova |
| |
| No 11 (2016) |
TERIFLUNOMIDE - A NEW TABLETED DRUG FOR THERAPY OF REMITTING DISSEMINATED SCLEROSIS (REVIEW) |
Abstract
PDF (Rus)
|
|
E. V. POPOVA, A. N. BOYKO, M. V. DAVYDOVSKAYA, S. N. ZOLOTOVA, N. V. KHACHANOVA, S. N. SHARANOVA |
| |
| No 11 (2016) |
TREATMENT PROBLEMS OF PATIENTS WITH MULTIPLE SCLEROSIS OF CHILDBEARING AGE |
Abstract
PDF (Rus)
|
|
E. V. POPOVA, S. N. SHARANOVA, A. N. BOYKO |
| |
| No 10 (2015) |
Questions of management of patients with hard-to-treat remitting multiple sclerosis |
Abstract
PDF (Rus)
|
|
E. V. Popova , M. V. Melnikov , A. N. Boiko , V. V. Murugin , M. V. Paschenkov |
| |
| No 18 (2015) |
Some risk management issues in teriflunomide treatment of patients with remitting multiple sclerosis |
Abstract
PDF (Rus)
|
|
N. Y. Lasch |
| |
| No 18 (2015) |
Endothelial dysfunction in multiple sclerosis and management options using alpha-lipoic acid |
Abstract
PDF (Rus)
|
|
N. N. Spirina , N. N. Spirin , A. N. Boyko |
| |
| No 18 (2015) |
Dimethyl fumarate: the new tableted preparation for the treatment of multiple sclerosis |
Abstract
PDF (Rus)
|
|
E. V. Popova , N. V. Khachanova , N. Y. Lasch , Е. V. Orlova , A. N. Boyko |
| |
| No 5 (2015) |
Selecting the best treatment for multiple sclerosis |
Abstract
PDF (Rus)
|
|
A. N. Boyko |
| |
| No 5 (2015) |
Teriflunomide in patients with multiple sclerosis |
Abstract
PDF (Rus)
|
|
N. Y. Lasch, A. N. Boyko |
| |
| No 10 (2015) |
New features of glatiramer acetate for the treatment of remitting multiple sclerosis |
Abstract
PDF (Rus)
|
|
N. Y. Lasch |
| |
| No 5 (2014) |
Fingolimod for the treatment of remitting multiple sclerosis: experience of the Moscow Multiple Sclerosis Center (MMSC) |
Abstract
PDF (Rus)
|
|
E. V. Popova, A. A. Yalymov, A. N. Boyko, M. V. Davydovskaya, E. V. Kolyak, O. V. Traktirskaya, N. V. Khachanova, S. G. Schur |
| |
| No 10 (2014) |
Natalizumab in the treatment of multiple sclerosis. Experience of the Moscow Multiple Sclerosis Center (MMSC) |
Abstract
PDF (Rus)
|
|
E. V. Popova, A. N. Boyko, M. V. Davydovskaya, O. V. Boyko, N. V. Khachanova |
| |
| 1 - 28 of 28 Items |
|
